{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:59:31Z","timestamp":1791295171763,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.bcmd.2012.04.002","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T11:01:01Z","timestamp":1336042861000},"page":"53-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment"],"prefix":"10.1016","volume":"49","author":[{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djazia","family":"Heraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2012.04.002_bb0005","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/bmj.286.6381.1864","article-title":"Serum ferritin concentration in Gaucher's disease","volume":"286","author":"Morgan","year":"1983","journal-title":"BMJ"},{"key":"10.1016\/j.bcmd.2012.04.002_bb0010","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiological, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine"},{"key":"10.1016\/j.bcmd.2012.04.002_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/bcmd.2002.0511","article-title":"Correlation of bone marrow response with hematological, biochemical and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients","volume":"28","author":"Poll","year":"2002","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1365-2141.2007.06701.x","article-title":"Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease","volume":"138","author":"Hughes","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2141.2007.06716.x","article-title":"Consensus recommendations","volume":"138","author":"Beutler","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/ajh.21721","article-title":"Hyperferritinemia and iron overload in type 1 Gaucher disease","volume":"85","author":"Stein","year":"2010","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1399-0004.2005.00563.x","article-title":"Prevalence of C282Y and H63D in Jewish populations and clinical implications of H63D homozygosity","volume":"69","author":"Matas","year":"2006","journal-title":"Clin. Genet."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0040","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1006\/bcmd.1997.0125","article-title":"HLH-H mutations in the Ashkenazi Jewish population","volume":"23","author":"Beutler","year":"1997","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0045","first-page":"503","article-title":"Epidemiologic, clinical, biological and therapeutic aspects of Gaucher disease","volume":"32","author":"Stirnemann","year":"2003","journal-title":"Presse Med."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ajh.1141","article-title":"Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes","volume":"68","author":"Emmenegger","year":"2001","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0060","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar3111","article-title":"Bone events and evolution of biologic markers in Gaucher disease before and during treatment","volume":"12","author":"Stirnemann","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bcmd.2009.08.002","article-title":"The clinical course of untreated Gaucher disease in 22 patients over 10 years: haematological and skeletal manifestations","volume":"43","author":"Piran","year":"2009","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bcmd.2010.10.014","article-title":"Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease","volume":"46","author":"Stirnemann","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2012.04.002_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.04.002_bb0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbadis.2007.04.002","article-title":"Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease","volume":"1772","author":"Van Breemen","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcmd.2012.04.002_bb0085","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secdretory way","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2012.04.002_bb0090","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-med-050109-142444","article-title":"Hepcidin and disorders of iron metabolism","volume":"62","author":"Ganz","year":"2011","journal-title":"Annu. Rev. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612000873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979612000873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:28:43Z","timestamp":1761049723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979612000873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1079979612000873"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.04.002","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2012.04.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}